We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Test Specifically Detects Mobile Colistin Resistance in Isolates

By LabMedica International staff writers
Posted on 22 Feb 2017
Print article
Image: Enrichment of bacterial cultures (Photo courtesy of DZIF and JLU).
Image: Enrichment of bacterial cultures (Photo courtesy of DZIF and JLU).
Scientists have evaluated a commercially available LAMP-based assay for rapid detection of the plasmid-encoded mobile colistin resistance gene mcr-1 in Enterobacteriaceae isolates. With further development and evaluation, it can likely also be used in hospitals and for livestock.

Scientists from the German Center for Infection Research (DZIF) and the Justus Liebig University (JLU) Giessen (also Giessen University) evaluated the test, which detects the mcr-1 within 20 minutes.

Colistin is used as a “last-resort antibiotic” for multidrug-resistant pathogens, especially in hospitals. However, some gut bacteria have become insensitive to colistin due to the mobile colistin resistance gene mcr-1. In early 2016, bacteria carrying mcr-1 were detected in Germany for the first time and there is growing concern that it may develop into a superbug against which even emergency antibiotics are no longer effective. Risk of further spread of this colisitin resistance is high because it takes place through plasmids, which are transferred between different types of bacteria relatively easily.

“Confirming the mobile mcr-1 resistance gene as rapidly as possible is important so as to prevent its further spread,” emphasized Linda Falgenhauer, DZIF scientist at Giessen University and a co-first-author of this study. She, with colleagues from Giessen University and from the research association RESET, tested a rapid genotypic resistance test for colistin that is already commercially available. “This is the only way with which mobile resistance can be differentiated from common resistance, because phenotypically they are the same,” said co-first-author Can Imirzalioglu, DZIF scientist at Giessen University.

For the evaluation of this test, AmplexBiosystems GmbH provided the testing kits free of charge. The scientists tested 104 bacterial isolates from animals, humans, and the environment: the results were compared to those from complete genome sequencing or PCR, and demonstrated 100% sensitivity and specificity. So the test could clearly differentiate between common colistin resistance and mobile resistance located on plasmids. However, applying the test directly to clinical samples has not yet been evaluated, it only been applied to bacterial cultures.

“The test results become available in only twenty minutes,” said co-author Judith Schmiedel, from the Giessen team, “With the conventional procedure, it takes several hours to get results. Additionally, the system is very uncomplicated, so it should be developed further for future use in hospitals as well as for livestock farming and food production.” With an “interdisciplinary collaboration, we are following the One Health approach which takes into account the systemic connections between humans, animals, the environment, and health in order to fight antibiotic resistance,” said Prof. Trinad Chakraborty, of JLU Giessen and coordinator of the DZIF partner-site Giessen-Marburg-Langen.

The study, by Imirzalioglu C et al, was published online ahead of print January 30, 2017, in the journal Antimicrobial Agents and Chemotherapy.

New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.